Dermabrasion in CO
Dermabrasion in CO section, includes general infrmation about Dermabrasion Procedure, Dermabrasion CO Local News, Dermabrasion CO Surgeon Locator and other Dermabrasion related material.
Dermabrasion Procedure
This method uses mechanical scraping in order to make the skin smoother by removing the superficial layers. Modern techniques and special electrical devices are used today. These can smoothen the skin scars which were caused by accidents, burns and acne. The aim of this technique is to smoothen the skin to a homogenous appearance which eliminates the height differences causes by sunken and protruding scars. As in chemical peeling, dermabration also removes the outer layers. The difference is that while peeling is being spread all over the surface, dermabration is applied to specific areas therefore better control on the depth of penetration is achieved.
Scars resulting from acne usually create small (2-3mm) craters. They usually appear on oily skin, which reacts poorly to chemical peeling, therefore, dermabration is the treatment of choice.
This method is not suitable for all parts of the body. It is usually used for treating the face, however, not every part of the face can be scraped, for example: the eyelids have a very thin and delicate skin that cannot be dermabrated.
Dermabration cannot make the scars completely disappear, it only blurs them and makes them look similar to the surrounding surface. If the scar is protruding, that would make it look more flat. If the scar is sunken, that would make the surface around look more flat.
The procedure takes from a few minutes up to 90 minutes, depending on the area involved. People from all age groups may be candidates for this procedure.
The healing process depends on patient's age, skin color and type, as well as other medical conditions. The surgeon uses a device called a dermatome which has an electric blaze that moves very fast while removing the outer skin layers.
Every procedure has its risks. The most common phenomenon is pigmentation changes, either to brighter or to darker color. Others include scar creation, usually caused by over-scraping (therefore many surgeons prefer to repeat the treatment several times). Tiny white spots can appear on your skin. It usually disappears, either by themselves or by using a sponge. Infection may also be possible.
After the treatment your skin will be reddish and swollen. That will disappear within a few days. It takes some time to see the final results. The most important thing is to avoid sun exposure, chlorinated water and any activity which may harm the area. Take the necessary precausions according to your surgeon's instructions.
Other Dermabrasion Procedures
All Skin Procedures
Dermabrasion CO (current)
Dermabrasion CO Chemical Peel
Dermabrasion CO Hyperhydrosis
Dermabrasion CO Laser Hair Removal
Dermabrasion CO Collagen Injections
More CO info...
Colombia By car Enter from Venezuela by the San Cristobal-C?cuta pass.
Enter from Ecuador by the Tulc?n-Ipiales(Rumichaca) pass.
Colombia By plane There are regular international flights into major cities including Barranquilla, Cartagena, Cali, Medellin and Bogota as well as to other smaller cities in the borders with Venezuela and Ecuador.
There are daily direct flights to and from the U.S, Canada, Mexico, Costa Rica, Panama, Spain, France, and South America.
Taxis are regulated, reasonably priced and safe from the airports. A taxi ride from the airport to the central business district in Bogota, takes approximately 20 minutes.
Plastic Surgery News...
- Rwanda recently launched a male circumcision program in an effort to help reduce the spread of HIV and other sexually transmitted infections, BBC News reports. Innocent Nyaruhirira, Rwanda's HIV/AIDS minister, said the program initially will target infants, the army, police and university students (BBC News, 1/22).Rwanda in September 2007 announced plans to launch the campaign.
Context Gene expression profiling may be useful for prognostic and therapeutic strategies in breast carcinoma.
Objectives To demonstrate the value in integrating genomic information with clinical and pathological risk factors, to refine prognosis, and to improve therapeutic strategies for early stage breast cancer.
Design, Setting, and Patients Retrospective study of patients with early stage breast carcinoma who were candidates for adjuvant chemotherapy; 964 clinically annotated breast tumor samples (573 in the initial discovery set and 391 in the validation cohort) with corresponding microarray data were used. All patients were assigned relapse risk scores based on their respective clinicopathological features. Signatures representing oncogenic pathway activation and tumor biology/microenvironment status were applied to these samples to obtain patterns of deregulation that correspond with relapse risk scores to refine prognosis with the clinicopathological prognostic model alone. Predictors of chemotherapeutic response were also applied to further characterize clinically relevant heterogeneity in early stage breast cancer.
Main Outcome Measures Gene expression signatures and clinicopathological variables in early stage breast cancer to determine a refined estimation of relapse-free survival and sensitivity to chemotherapy.
Results In the initial data set of 573 patients, prognostically significant clusters representing patterns of oncogenic pathway activation and tumor biology/microenvironment states were identified within the low-risk (log-rank P = .004), intermediate-risk (log-rank P = .01), and high-risk (log-rank P = .003) model cohorts, representing clinically important genomic subphenotypes of breast cancer. As an example, in the low-risk cohort, of 6 prognostically significant clusters, patients in cluster 4 had an inferior relapse-free survival vs patients in cluster 1 (log-rank P = .004) and cluster 5 (log-rank P = .03). Median relapse-free survival for patients in cluster 4 was 16 months less than for patients in cluster 1 (95% CI, 7.5-24.5 months) and 19 months less than for patients in cluster 5 (95% CI, 10.5-27.5 months). Multivariate analyses confirmed the independent prognostic value of the genomic clusters (low risk, P = .05; high risk, P = .02). The reproducibility and validity of these patterns of pathway deregulation in predicting relapse risk was established using related but not identical clusters in the independent validation cohort. The prognostic clinicogenomic clusters also have unique sensitivity patterns to commonly used cytotoxic therapies.
Conclusions These results provide preliminary evidence that incorporation of gene expression signatures into clinical risk stratification can refine prognosis. Prospective studies are needed to determine the value of this approach for individualizing therapeutic strategies.